Eribulin as First-Line Therapy for Metastatic HER2-Negative Breast Cancer
Joyce A. O’Shaughnessy, MD, from Baylor Charles A. Sammons Cancer Center, discusses the results of a recent breast cancer study.
Clinical Pearls
Joyce A. O’Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center; Texas Oncology, PA/US Oncology, Dallas, Texas, discusses the results of a recent breast cancer study.
- This study looked at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
- Overall response rate was 29%.
- Clinical benefit rate was 52%.
- Median PFS was 6.8 months.
- Responses were seen regardless of ER status.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
